ATEC:NGS-Alphatec Holdings Inc. (USD)

EQUITY | Medical Devices | Nasdaq Global Select

Last Closing

USD 9.28

Change

-0.42 (-4.33)%

Market Cap

USD 0.05B

Volume

1.91M

Analyst Target

USD 9.80
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alphatec Holdings Inc is a medical technology company. It is engaged in the design, development, manufacturing and marketing of products for the surgical treatment of spine disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

-1.81 (-2.43%)

USD 27.48B
PODD Insulet Corporation

-6.04 (-2.20%)

USD 16.52B
BRKR Bruker Corporation

-0.10 (-0.18%)

USD 8.98B
MASI Masimo Corporation

+0.83 (+0.52%)

USD 7.71B
PRCT Procept Biorobotics Corp

-3.30 (-3.45%)

USD 4.99B
AXNX Axonics Modulation Technologie..

-0.04 (-0.06%)

USD 3.60B
TMDX TransMedics Group Inc

+1.32 (+1.44%)

USD 2.89B
NARI Inari Medical Inc

-0.53 (-1.03%)

USD 2.85B
LIVN LivaNova PLC

+0.58 (+1.09%)

USD 2.80B
UFPT UFP Technologies Inc

-28.76 (-8.37%)

USD 2.65B

ETFs Containing ATEC

XHE SPDR® S&P Health Care Eq.. 2.56 % 0.35 %

-1.55 (-1.68%)

USD 0.22B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.58% 42% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.58% 42% F 21% F
Trailing 12 Months  
Capital Gain -12.70% 51% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.70% 51% F 30% F
Trailing 5 Years  
Capital Gain 34.10% 83% B 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.10% 83% B 61% D-
Average Annual (5 Year Horizon)  
Capital Gain 65.49% 84% B 89% A-
Dividend Return 65.49% 84% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 160.26% 25% F 15% F
Risk Adjusted Return 40.86% 90% A- 71% C-
Market Capitalization 0.05B 83% B 75% C

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 50.98 3% 3%
Price / Cash Flow Ratio -17.52 83% 87%
Price/Free Cash Flow Ratio -18.89 92% 92%
Management Effectiveness  
Return on Equity -21,137.14% 1% 0%
Return on Invested Capital -31.41% 54% 28%
Return on Assets -12.10% 60% 32%
Debt to Equity Ratio 502.40% 3% 4%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector